(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...

Merck & Co. is facing a class action lawsuit over Gardasil sales projections. Learn how to recover losses with Levi & ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Eli Lilly and Company, Johnson & Johnson, Pfizer, Merck & Co., Inc., and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. These ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Dogs of the Dow can be described as the 10 highest yielding stocks that are within the DJI. Read more to see the best Dog of ...

The majority of the market isn't seeing the bigger picture for these stocks and their underlying companies. Big mistake.

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...